Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04146051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jul 31, 2025 → Jan 5, 2026
See other at-risk trials from Cartesian Therapeutics

Record History

  1. Primary completion pushed from Jul 31, 2025 to Jan 5, 2026 Completion pushed from Mar 31, 2026 to Sep 30, 2026v20 Show 1 more changeShow less
    • Completion pushed from Mar 31, 2026 to Sep 30, 2026
  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Mar 31, 2025 to Jul 31, 2025 · Site details revised at 15 of 15 sitesv19 Show 2 more changesShow less
    • Primary completion date: Mar 31, 2025 to Jul 31, 2025
    • Site details revised at 15 of 15 sites
  3. Primary endpoint revised Secondary endpoints revised (4)v18 Show 1 more changeShow less
    • Secondary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Dec 1, 2023 to Mar 31, 2025 Completion date: Dec 1, 2023 to Mar 31, 2026v17 Show 1 more changeShow less
    • Completion date: Dec 1, 2023 to Mar 31, 2026
  5. Study sites revised (15)v16 See this version in full on ClinicalTrials.gov ↗
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites revised (15)v15 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 9 to 15v14
  3. Study sites: 11 to 9v13
  4. Site details revised at 1 of 11 sitesv12
  5. Phase: Phase 1/2 to Phase 2 Enrollment target: 18 to 30 · Primary completion date: Dec 1, 2022 to Dec 1, 2023 · Primary endpoint revised · 4 morev11 Show 7 more changesShow less
    • Enrollment target: 18 to 30
    • Primary completion date: Dec 1, 2022 to Dec 1, 2023
    • Primary endpoint revised
    • Secondary endpoints: 1 to 4
    • Site contacts updated at 9 of 11 sites
    • Study arms: 2 to 3
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 12 to 11v10
  7. Study sites: 8 to 12v9
  8. Study sites: 3 to 8v8
  9. Study sites: 4 to 3v7
  10. Primary completion date: Nov 1, 2021 to Dec 1, 2022 Completion date: Apr 1, 2022 to Dec 1, 2023v6 Show 1 more changeShow less
    • Completion date: Apr 1, 2022 to Dec 1, 2023
  11. Study sites: 2 to 4v5
  12. Re-verified, no change to tracked fieldsv4
  13. Study sites: 1 to 2 Start date changed from estimate of Nov 1, 2019 to Dec 4, 2019v3 Show 1 more changeShow less
    • Start date changed from estimate of Nov 1, 2019 to Dec 4, 2019
  14. Secondary endpoint revisedv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
Trial Details
NCT Number NCT04146051
Lead Sponsor Cartesian Therapeutics
Conditions Myasthenia Gravis, Generalized
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov